Table 1.
Baseline clinical and laboratory features of 40 triple-negative ET patients.
| Patients (n = 40) | |
|---|---|
| Male/female | 16/24 |
| Age (years), median (range) | 50.2 (20–85) |
| Hb (g/dl), median (range) | 13.8 (10.8–16.1) |
| Hct (%), median (range) | 41.8 (33.2–49.1) |
| WBC count (×109/L), median (range) | 8.01 (5.23–12.5) |
| PLT count (×109/L), median (range) | 595 (443–2456) |
| LDH (IU/L), median (range) | 220 (105–462) |
| Serum erythropoietin (mIU/mL), median (range) | 7.15 (0.6–14.1) |
| Circulating CD34+ cells (/μl), median (range) | 5 (1–9) |
| Cytogenetic abnormalities, n (%) | 7 (17.5) |
| Palpable splenomegaly, n (%) | 5 (12.5) |
| Previous thrombosis, n (%) | 2 (5.0) |
| Previous hemorrhages, n (%) | / |
| Conventional thrombotic score, n (%) | |
| Low risk | 25 (62.5) |
| High risk | 15 (37.5) |
| IPSET-Thrombosis, n (%) | |
| Low risk | 28 (70.0) |
| Intermediate risk | 10 (25.0) |
| High risk | 2 (5.0) |
| Revised IPSET-Thrombosis, n (%) | |
| Very Low risk | 26 (65.0) |
| Low risk | / |
| Intermediate risk | 12 (30.0) |
| High risk | 2 (5.0) |
| Cytoreductive therapy, n (%) | 22 (55.0) |
| Antiplatelet therapy, n (%) | 37 (92.5) |
| Follow-up (years), median (range) | 7.0 (1.2–36.8) |
| Deceased, n (%) | 4 (10.0) |
ET, essential thrombocythemia; Hb, hemoglobin; Hct, hematocrit; WBC, white blood cells; PLT, platelets; LDH, lactate dehydrogenase.